|Awarded On||February 21, 2019|
|Title||Role of PARP-1 in Estrogen Receptor Enhancer Function and Gene Regulation Outcomes in Breast Cancers|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||W. Lee Kraus|
A key hurdle in developing better treatments for breast cancers is a lack of understanding of the mechanisms that promote their growth, and why some breast cancers grow in response to estrogens, while others do not. Olaparib, a drug that targets PARP-1, a protein involved in many important cellular functions, was recently approved by the FDA for the treatment of breast cancers with certain types of DNA repair defects. Preliminary results suggest that Olaparib and other PARP inhibitors may also be useful for treating breast cancers that express estrogen receptor alpha (ERa) and are responsive to the hormone estrogen. In this regard, we are studying the interplay between ERa and PARP-1 in ...